Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

A plasmapheresis system and a method for operating a plasmapheresis system are provided by which a volume of plasma product (i.e., anticoagulated plasma) so that that the targeted volume of pure plasma in the plasma product is determined based on donor-specific characteristics. In particular, the targeted amount of pure plasma to be collected is based on the weight, or the weight and the height, of the donor. The targeted volume of pure plasma to be collected, TVP, may be a multiple of the donor's weight. Alternatively, TVP may be a multiple of the donor's total blood volume, TBV, with the TBV of the donor being determined based on the donor's weight and height. A target volume for the plasma product to be collected, TVPP, is established, and separation of whole blood into a plasma component and a second component continues until the volume of plasma product in a collection container equals TVPP.

System and methods are provided for treating a patient that include a delivery device sized for introduction into a target site within a patient's body, a source of one or more therapeutic and/or diagnostic agents coupled to the delivery device, and a tubular member sized for introduction into the patient's vasculature to isolate the thoracic duct. Once the thoracic duct is isolated, fluid may be removed from the thoracic duct, e.g., to prevent the agents that transit from the target site into the thoracic duct from entering the patient's vasculature, and/or to modulate flow through the thoracic duct to modulate concentration and/or resident time of the agents at the target site. The one or more agents may include particles sized for preferential transit into the lymphatic system.

An extracorporeal blood treatment apparatus comprises a blood treatment device (2), an extracorporeal blood circuit, a blood pump (8) configured to be coupled to a blood withdrawal line (6) of the extracorporeal blood circuit. A closed fluid line (10) is connected to an inlet port (4a) and to an outlet port (4b) of a fluid chamber (4) of the blood treatment device (2), wherein the closed fluid line (10) together with the fluid chamber (4) forms a recirculation loop. An evacuation line (15) departs from the closed fluid line (10). A warming device (13) and a recirculation pump (17) are coupled or configured to be coupled to the closed fluid line (10). At least one temperature sensor (22) is operative on the extracorporeal blood circuit and it is configured to sense a blood temperature (Tb). A control unit (25), connected to the warming device (13), to the recirculation pump (17) and to the temperature sensor (22), is configured to execute the following procedure: receiving from the temperature sensor (22) at least a signal correlated to the blood temperature (Tb); adjusting the blood temperature (Tb) by controlling at least one of the warming device (13) and the recirculation pump (17).

A system for collecting plasma comprises a separator to separate whole blood from a donor into a plasma product and red blood cells, an anticoagulant line to introduce anticoagulant to the whole blood, a touchscreen, and a controller. The controller is configured to receive donor parameters electronically from a donor management system. The controller is configured to use a target volume for plasma product and/or raw plasma which is based at least in part on donor height and weight used to calculate total donor blood volume, the target volume for plasma product and/or raw plasma based on the total donor blood volume. The controller is configured to control the system to operate at least three draw and return phases to withdraw whole blood from a donor and separate the whole blood into the plasma product and the red blood cells and to return the red blood cells to the donor.

The present invention relates to a system (100) for extracorporeal blood treatment comprising a first inlet (1) for introducing a bloodstream to be treated into the system (100), three blood treatment apparatus (A, D, G), as well as an outlet (2) for discharging a treated bloodstream from the system (100), wherein the system comprises an adsorber apparatus (A) and/or a plasma separator apparatus, a dialysis apparatus (D) and a gas exchange apparatus (G), and wherein the three blood treatment apparatus (A, D, G) are sequentially connected in series in a functional state of system (100) application between the inlet (1) and the outlet (2) of the system relative to a direction of blood flow of a bloodstream to be treated and can be consecutively perfused extracorporeally by a bloodstream to be treated. The present invention further relates to a treatment apparatus comprising such a system, a kit comprising the components of such a system, a method for operating such a system (100) as well as a method for extracorporeal blood treatment with such a system (100).

A medical fluid delivery system including remote machine updating and control is disclosed. An example medical fluid delivery system includes a medical fluid delivery device for a patient. The medical fluid delivery system also includes a server in communication with the medical fluid delivery device and a software application for a mobile device. The software application causes an icon to be displayed representing the medical fluid delivery device. The medical fluid delivery system further includes a first communication link between the medical fluid delivery device and the server, and a second communication link between the server and the software application. The software application receives status updates from the medical fluid delivery device via the server and the first and second links.

Provided is a blood filter that resists deterioration in properties as a result of electron beam sterilization treatment performed before or during use as a blood filter, has durability, dimensional stability, and chemical resistance at excellent levels, also has biocompatibility, and resists deterioration in properties even upon the electron beam sterilization treatment. The blood filter according to the present invention includes a nonwoven fabric made of PEEK fibers. Preferably, the blood filter according to the present invention has an average pore size of 3 to 280 μm and has a porosity of 15% to 70%; and the PEEK fibers have an average fiber diameter of 10 μm or less.

The present system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. In some embodiments, the system includes an immobilized capture ligand of a single chain TNFα. The system and method are useful for the treatment of different cancer types, stages and severity.

The invention is directed to the removal of serum gal-3 from circulation by plasmapheresis, comprising at least in part donor apheresis, using gal-3 binding agents in either a fixed bed, or in a form easily removed, such as by being complexed with magnetic particles. This method, on its own, brings a sharp reduction and relief from the inflammation and fibroses that can be induced by circulating gal-3. The process may be combined with the administration of gal-3 binding agents, such as modified citrus pectin, to further lower unbound gal-3 levels, to the point where gal-3 in the tissues may be addressed. This method may also be combined with removal of TNF receptors to provide an effective treatment for cancer.